Loading video...

Video Failed to Load

There was a problem loading this video. This could be due to a temporary network issue or the video might be unavailable.

Introducing Latent-X2 — AI-generated antibodies with drug-like developability and low immunogenicity in human panels, zero-shot. Technical report: Blog: Apply for access: [email protected]

Simon Kohl

3,071 subscribers

54,814 views • 9 months ago •via X (Twitter)

Health & Wellness Education Science & Technology

Anya Rossi• Live Now

Private livecam show

29 Comments

Jeff Dean9 months ago

Congrats! 🎉

Simon Kohl9 months ago

Thank you, Jeff!!!

Simon Kohl9 months ago

Latent-X2 achieves high-affinity binders across modalities: scFv fragments — down to low picomolar VHH nanobodies — nanomolar affinities Macrocyclic peptides — hits on K-Ras, matching trillion-scale screens Testing just 4-24 designs per experiment. And as part of our report, we release lab-confirmed binder sequences for each of them.

Simon Kohl9 months ago

But the real breakthrough isn't binding, it's developability. Our designs match or exceed approved therapeutics in head-to-head comparison. Expression yield, thermostability, polyreactivity — drug-like from the first generation.

Simon Kohl9 months ago

And for the first time: immunogenicity assessment of an AI-generated antibody. Latent-X2 VHH binders cleared ex vivo T-cell activation and cytokine release assays across a ten-donor human panel. A critical milestone for clinical translation.

Simon Kohl9 months ago

To enable reproduction, we're publishing the sequence and structure of a lab-validated antibody design for each target — accessible on the Latent Labs Platform without sign-in. See the lab-validated examples section on:

Simon Kohl9 months ago

Super excited to also welcome Stefan Oschmann, former CEO of Merck KGaA, to our strategic advisory board. Drug discovery has long been bottlenecked not by hits, but by development. With Latent-X2, we're getting closer to designing the right molecule from the start.

Simon Kohl9 months ago

Just five months after Latent-X1. Grateful to the team for pushing the frontier. Latent-X2 is available on the Latent Labs Platform, via API and in partnerships with us. Reach out: [email protected] More to come. 🚀

Simon Kohl9 months ago

Check out the antibody design workflow on our platform. I am proud of how easy to use this frontier technology can feel.

Robin Rombach9 months ago

🔥 congrats, Simon!

Simon Kohl9 months ago

Thank you @robrombach - and ofc amazing to have you contribute!

Rishabh9 months ago

Congrats to the team!! Looks awesome :D

Simon Kohl9 months ago

Thank you, Rishabh!

Chaitanya K. Joshi9 months ago

Congrats team!

Simon Kohl9 months ago

Thank you Chaitanya!

Karsten Kreis9 months ago

Congrats to you and the team, Simon! 🔥

Simon Kohl9 months ago

Thanks a lot Karsten!

Anthara Fairooz9 months ago

Exciting innovation! Looking forward to seeing the impact of Latent-X2.

Rishabh Poddar9 months ago

I wish more people did work like this!

Rahul9 months ago

Congratulations @saakohl! Latent-X is a game-changer for computational biology and drug discovery, pushing button for picomolar binders could slash timelines on undruggable targets like never before. AI in Science exploding! 🔥

nabajit (bio/acc)9 months ago

very cool

MrHonkster9 months ago

Saving to read later

Amy - AI Girl9 months ago

Exciting advancement in AI-generated antibodies! Great potential for health innovation.

Arda Göreci9 months ago

Congrats Simon!

PurePckg9 months ago

May I ask who was responsible for the frontend development using Mol*? The glass‑like rendering and the elegant handling of selections in each component are truly impressive.

Ava Grace9 months ago

Exciting innovation in AI-generated antibodies!

Tony Kulesa9 months ago

🔥

Evgenii9 months ago

Nice affinities. It's a pity that no proofs are presented.

Sam Dare9 months ago

@micaelabazo @metanova_labs wen?

Related Videos

Today we're launching Latent-Y: the world's first autonomous agent for drug design, lab-validated end to end. Give it a research goal. Latent-Y reasons, designs, iterates, and delivers lab-ready antibodies, autonomously or collaboratively, with the biological reasoning of a PhD protein design expert. Technical report: Blog post: Apply for access:

Today we're launching Latent-Y: the world's first autonomous agent for drug design, lab-validated end to end. Give it a research goal. Latent-Y reasons, designs, iterates, and delivers lab-ready antibodies, autonomously or collaboratively, with the biological reasoning of a PhD protein design expert. Technical report: Blog post: Apply for access:

Simon Kohl

121,575 views • 6 months ago

Introducing Latent-X — our all-atom frontier AI model for protein binder design. State-of-the-art lab performance, widely accessible via the Latent Labs Platform. Free tier: Blog: Technical report:

Introducing Latent-X — our all-atom frontier AI model for protein binder design. State-of-the-art lab performance, widely accessible via the Latent Labs Platform. Free tier: Blog: Technical report:

Simon Kohl

57,495 views • 1 year ago

Introducing ManipGen: a sim2real agent for zero-shot manipulation. ManipGen handles complex tasks in the real world like organizing shelves, tidying cluttered tables, and more – all from text input and with on human demonstrations!

Introducing ManipGen: a sim2real agent for zero-shot manipulation. ManipGen handles complex tasks in the real world like organizing shelves, tidying cluttered tables, and more – all from text input and with on human demonstrations!

Deepak Pathak

58,160 views • 1 year ago

Today, we expand zero-shot drug design beyond binding to the design of multifunctional medicines, the intracellular proteome, and state-of-the-art atomic precision with our model, JAM-2. In a new report (below), we show: 1. The first drug-grade, fully computationally designed multispecific antibodies against five peptide-MHCs: Routine picomolar T-cell activation/cell-killing EC50s, >100-fold selectivity, and drug-like developability 2. The first fully generatively designed, drug-grade dual-variant KRAS G12 multispecifics: They recruit primary T-cells from human donors to kill G12V and G12C presenting cells at pM to single-digit-nM potency, completely sparing wild-type. 3. Atomic accuracy, from sequence alone: Angstrom-level agreement between Cryo-EM and JAM-2 de novo designs, requiring only target sequences (not structure) as input. 4. Unrivaled speed with an AI-native in-house wet lab: Designed, built, and tested five programs in one parallelized campaign, end-to-end in-house in ~6 weeks. 5. A higher validation bar for AI-generated drug candidates: In a field increasingly rife with hype and uneven standards of proof, we provide the highest quality public wet-lab validation of AI-designed antibodies to date. We share experimental methods in full, and invite folks to adopt and build on these standards. Truly individualized therapies will be the most important contribution of AI in drug design. These advances help accelerate this future.

Today, we expand zero-shot drug design beyond binding to the design of multifunctional medicines, the intracellular proteome, and state-of-the-art atomic precision with our model, JAM-2. In a new report (below), we show: 1. The first drug-grade, fully computationally designed multispecific antibodies against five peptide-MHCs: Routine picomolar T-cell activation/cell-killing EC50s, >100-fold selectivity, and drug-like developability 2. The first fully generatively designed, drug-grade dual-variant KRAS G12 multispecifics: They recruit primary T-cells from human donors to kill G12V and G12C presenting cells at pM to single-digit-nM potency, completely sparing wild-type. 3. Atomic accuracy, from sequence alone: Angstrom-level agreement between Cryo-EM and JAM-2 de novo designs, requiring only target sequences (not structure) as input. 4. Unrivaled speed with an AI-native in-house wet lab: Designed, built, and tested five programs in one parallelized campaign, end-to-end in-house in ~6 weeks. 5. A higher validation bar for AI-generated drug candidates: In a field increasingly rife with hype and uneven standards of proof, we provide the highest quality public wet-lab validation of AI-designed antibodies to date. We share experimental methods in full, and invite folks to adopt and build on these standards. Truly individualized therapies will be the most important contribution of AI in drug design. These advances help accelerate this future.

Nabla Bio

180,591 views • 3 months ago

Introducing: Argent Lens 🔍 A design review tool for agent-generated UI. With Lens your AI-agent can propose several design variants. You pick the one you like, leave comments on any part of the UI, and apply the changes. Now available in experimental.

Introducing: Argent Lens 🔍 A design review tool for agent-generated UI. With Lens your AI-agent can propose several design variants. You pick the one you like, leave comments on any part of the UI, and apply the changes. Now available in experimental.

Software Mansion

30,369 views • 3 months ago

I finally gave in and recorded everything I know about AI marketing. Introducing: ✨ The AI Marketing Masterclass ✨ • 14 lessons • 3 hours • Zero to AI-native marketer You don't have to be technical! Grab it for $149 until midnight tonight.

I finally gave in and recorded everything I know about AI marketing. Introducing: ✨ The AI Marketing Masterclass ✨ • 14 lessons • 3 hours • Zero to AI-native marketer You don't have to be technical! Grab it for $149 until midnight tonight.

Corey Haines

12,264 views • 18 days ago

Today we launch Latent-Y, our drug design agent. 250 designs free every day for any approved researcher. We are also releasing the first lab results from researchers with early access: Ion channel inhibitors that work. CAR-T cells that kill tumour cells, now in vivo. Binders the malaria parasite cannot mutate away from. Full results: Apply for access:

Today we launch Latent-Y, our drug design agent. 250 designs free every day for any approved researcher. We are also releasing the first lab results from researchers with early access: Ion channel inhibitors that work. CAR-T cells that kill tumour cells, now in vivo. Binders the malaria parasite cannot mutate away from. Full results: Apply for access:

Simon Kohl

26,654 views • 2 months ago

Introducing OpenDocs. A new program in partnership with _ a r t e f a c t o _ providing production support and access to creative AI to documentarians from diverse communities and regions. Learn more and apply at

Introducing OpenDocs. A new program in partnership with _ a r t e f a c t o _ providing production support and access to creative AI to documentarians from diverse communities and regions. Learn more and apply at

Runway Studios

35,690 views • 2 years ago

Introducing the first agent for visual development. The Bubble AI Agent is here (in beta) — your in-editor partner that explains, troubleshoots, and builds with you. Now available on AI-generated apps. Read more:

Introducing the first agent for visual development. The Bubble AI Agent is here (in beta) — your in-editor partner that explains, troubleshoots, and builds with you. Now available on AI-generated apps. Read more:

Bubble

10,638 views • 11 months ago

Super impressive, this AI agent can use the web browser like a human. Just describe what you want it to do, and it will automatically operate Chrome for you to achieve your task. Apply for early access to HyperWrite:

Super impressive, this AI agent can use the web browser like a human. Just describe what you want it to do, and it will automatically operate Chrome for you to achieve your task. Apply for early access to HyperWrite:

Lior Alexander

217,721 views • 3 years ago

Introducing Gaslight Garage: a box where I put my phones and feed them AI-generated audio nonsense to make them think I want to buy stuff. Practical AI for the people. 👌 I'll report back if my ads change in the next weeks.

Introducing Gaslight Garage: a box where I put my phones and feed them AI-generated audio nonsense to make them think I want to buy stuff. Practical AI for the people. 👌 I'll report back if my ads change in the next weeks.

Karim Jedda

1,151,640 views • 1 year ago

introducing lipsync-1.9-beta, setting a new standard for lipsync quality it’s zero-shot—no training data needed. generate and edit natural speech seamlessly in any live action, animation, and AI-generated video this is the biggest update we’ve ever released, it’s the most natural lipsyncing model in the world 🔥 available now, try it in our app or via API 👇

introducing lipsync-1.9-beta, setting a new standard for lipsync quality it’s zero-shot—no training data needed. generate and edit natural speech seamlessly in any live action, animation, and AI-generated video this is the biggest update we’ve ever released, it’s the most natural lipsyncing model in the world 🔥 available now, try it in our app or via API 👇

sync. labs

129,213 views • 1 year ago

Most AI action clips feels like it was made by the same model on repeat. These 7 don’t. Every single one was generated with Seedance 2.0 in LTX. Different tones, different shot design, zero repetition. Grab the prompts below 🧵

Most AI action clips feels like it was made by the same model on repeat. These 7 don’t. Every single one was generated with Seedance 2.0 in LTX. Different tones, different shot design, zero repetition. Grab the prompts below 🧵

TechHalla

33,887 views • 3 months ago

Drop 5/14: Introducing Bulbul V3, our latest text-to-speech model. It raises the bar for how human it sounds, while being super robust. In an independent third-party human listening study, Bulbul V3 delivers the highest listener preference, and low error rates across use-cases and languages. See details in our blog, but first watch the video.

Drop 5/14: Introducing Bulbul V3, our latest text-to-speech model. It raises the bar for how human it sounds, while being super robust. In an independent third-party human listening study, Bulbul V3 delivers the highest listener preference, and low error rates across use-cases and languages. See details in our blog, but first watch the video.

Pratyush Kumar

424,540 views • 8 months ago

🔐 Introducing 1Password Unified Access, a new core capability within 1Password Extended Access Management that brings Zero Trust governance to every login, not just those behind SSO. With Unified Access: ✔️ Discover shared + sensitive accounts outside SSO ✔️ Apply Zero Trust governance to every login ✔️ Instantly rotate or revoke access ✔️ Give employees one place to access every app Now in public preview for eligible customers. 👉 Learn more and sign up: #IdentitySecurity #ZeroTrust #AccessManagement #XAM #UnifiedAccess #1Password

🔐 Introducing 1Password Unified Access, a new core capability within 1Password Extended Access Management that brings Zero Trust governance to every login, not just those behind SSO. With Unified Access: ✔️ Discover shared + sensitive accounts outside SSO ✔️ Apply Zero Trust governance to every login ✔️ Instantly rotate or revoke access ✔️ Give employees one place to access every app Now in public preview for eligible customers. 👉 Learn more and sign up: #IdentitySecurity #ZeroTrust #AccessManagement #XAM #UnifiedAccess #1Password

1Password

13,068 views • 8 months ago

Higgsfield Plugin for DaVinci Resolve is live. Generate footage in your timeline, draw on a clip to edit, and apply AI-generated LUTs to your scene. Remove backgrounds, reframe, upscale to 4K. Rebuild any shot to your camera, lens, and aperture on Cinema Studio.

Higgsfield Plugin for DaVinci Resolve is live. Generate footage in your timeline, draw on a clip to edit, and apply AI-generated LUTs to your scene. Remove backgrounds, reframe, upscale to 4K. Rebuild any shot to your camera, lens, and aperture on Cinema Studio.

Higgsfield AI 🧩

174,220 views • 4 months ago

Introducing 𝐀𝐋𝐎𝐇𝐀 𝐔𝐧𝐥𝐞𝐚𝐬𝐡𝐞𝐝 🌋 - Pushing the boundaries of dexterity with low-cost robots and AI. Google DeepMind Finally got to share some videos after a few months. Robots are fully autonomous filmed in one continuous shot. Enjoy!

Introducing 𝐀𝐋𝐎𝐇𝐀 𝐔𝐧𝐥𝐞𝐚𝐬𝐡𝐞𝐝 🌋 - Pushing the boundaries of dexterity with low-cost robots and AI. Google DeepMind Finally got to share some videos after a few months. Robots are fully autonomous filmed in one continuous shot. Enjoy!

Tony Zhao

354,625 views • 2 years ago

🤖 Introducing Taskade's AI Teams with Multi-Agent Collaboration, now in beta! Assemble your team of AI Agents for collaboration, intelligent responses, and dynamic interactions. They plan, execute, and manage tasks—all together! Reply 'AI Teams' for early access! ✨

🤖 Introducing Taskade's AI Teams with Multi-Agent Collaboration, now in beta! Assemble your team of AI Agents for collaboration, intelligent responses, and dynamic interactions. They plan, execute, and manage tasks—all together! Reply 'AI Teams' for early access! ✨

Taskade

29,743 views • 2 years ago

This morning we unveiled Utah’s approach to artificial intelligence: Pro-Human AI. Pro-Human AI means systems that keep people in the driver’s seat, strengthen learning and agency, and broaden opportunity for every Utahn. Utah is backing that vision with action: a new academic consortium, major workforce investments, and partnerships that accelerate responsible, human-centered innovation. More here:

This morning we unveiled Utah’s approach to artificial intelligence: Pro-Human AI. Pro-Human AI means systems that keep people in the driver’s seat, strengthen learning and agency, and broaden opportunity for every Utahn. Utah is backing that vision with action: a new academic consortium, major workforce investments, and partnerships that accelerate responsible, human-centered innovation. More here:

Governor Cox

16,877 views • 10 months ago